The multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster (Dm-dNK) is investigated for possible use as a suicide gene in combined gene/chemotherapy of cancer. The enzyme has broader substrate specificity and higher catalytic rate compared to herpes simplex type 1 thymidine kinase and other known dNKs. Although the enzyme has broad substrate specificity, it has a preference for pyrimidine nucleosides and nucleoside analogs. We have evaluated the substrate specificity and kinetic properties of Dm-dNK proteins containing M88R, V84A+M88R or V84A+M88R+ A110D mutations in the amino-acid sequence. These engineered enzymes showed a relative increase in phosphorylation of purine nucleoside analogs such as ganciclovir, 9-b-D-arabinofuranosylguanine and 2 0 ,2 0 -difluorodeoxyguanosine compared to the wild-type enzyme. The mutant enzymes were expressed in an osteosarcoma thymidine kinase-deficient cell line and the sensitivity of the cell line to nucleoside analogs was determined. The cells expressing the M88R mutant enzyme showed the highest increased sensitivity to purine nucleoside analogs with 8-to 80-fold decreased inhibition constant IC 50 compared to untransduced control cells or cells expressing the wild-type nucleoside kinase. In summary, our data show that enzyme engineering can be used to shift the substrate specificity of the Dm-dNK to selectively increase the sensitivity of cells expressing the enzyme to purine nucleoside analogs. Gene Therapy (2007) 14, 86-92.
Introduction
The expression of herpes simplex virus thymidine kinase (HSV-1 TK) in tumor cells and subsequent systemic chemotherapy with the nucleoside analog ganciclovir (GCV) has been used as a prototype for combined gene/ chemotherapy of malignant tumors. [1] [2] [3] The phosphorylation of GCV by HSV-1 TK is rate limiting for the pharmacological activation of GCV to its triphosphates form, and the kinetic properties of the thymidine kinase is one factor that determines the sensitivity of cancer cells to the nucleoside analog. Genetically engineered mutants of HSV-1 TK with improved kinetic properties for nucleoside analog phosphorylation have therefore been studied to develop improved nucleoside kinases to use in suicide gene therapy. 4, 5 For instance, mutation A167Y in HSV-1 TK resulted in an enzyme with retained phosphorylation of purine nucleoside analogs while losing affinity for pyrimidine nucleosides. 6 Cells expressing the enzyme showed increased sensitivity to GCV, demonstrating that it is possible to specifically alter the substrate specificity of a nucleoside kinase to improve its properties for nucleoside analog phosphorylation.
Nucleoside kinases from sources other than the viral thymidine kinases are investigated for suicide gene applications. The multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster (Dm-dNK) phosphorylates both purine and pyrimidine deoxyribonucleosides as well as several antiviral and anticancer nucleoside analogs. 7 The broad substrate specificity of this enzyme, together with a high catalytic rate, makes it unique among known dNKs. Expression of Dm-dNK in cancer cells increases the sensitivity to several cytotoxic nucleoside analogs, [8] [9] [10] rendering the enzyme a candidate for possible use as a suicide gene in combined gene/ chemotherapy of cancer. Although the enzyme has broad substrate specificity, it has a preference for pyrimidine nucleosides and nucleoside analogs. For instance, Dm-dNK does not phosphorylate GCV or several other guanosine nucleoside analogs. 7 Purine nucleoside analogs may induce a more efficient bystander cell killing than pyrimidine nucleoside analogs and the low affinity for purine nucleosides is a potential disadvantage of Dm-dNK for its use as a suicide gene. 5, 11 It was recently reported that mutations of only a few amino acids in Dm-dNK result in a shift in substrate specificity from pyrimidine to purine nucleosides phosphorylation.
M88 and A110 gained the ability to phosphorylate this nucleoside analog. It has also been shown that Dm-dNK with a 20 amino-acid deletion of the C-terminal had an even higher catalytic rate for deoxyribonucleosides compared to the wild-type enzyme. 13 We decided to investigate the possibility to design and construct mutated Dm-dNK with the ability to phosphorylate GCV while retaining its high catalytic rate and to study their enzymatic properties in a functional assay after cellular expression.
Results
Mutations of Dm-dNK at amino acids V84, M88 and A110 may alter the substrate specificity of Dm-dNK to enable the enzyme to phosphorylate purine nucleosides. 12 We decided to evaluate the kinetic properties of such mutants as well as determine if these enzymes could increase the sensitivity of cells to GCV and other purine nucleoside analogs. The three Dm-dNK mutants M88R, M88R+V84A and M88R+V84A+A110D were created by site-directed mutagenesis ( Figure 1 ). Truncation of the C-terminal 20 amino acids of the wild-type protein has been reported to increase the catalytic rate of the enzyme, without altering its substrate specificity. 13 Therefore, we also created truncated versions (D20) of the wild-type Dm-dNK as well as the M88R and M88R+V84A mutant proteins to evaluate how the truncation affected the kinetic properties of the enzymes.
The Dm-dNK proteins were recombinantly expressed in Escherichia coli and the relative phosphorylation efficiencies for deoxyribonucleosides relative to deoxythymidine (dThd), which is the preferred substrate of the wild-type enzyme, were determined using a phosphorylation assay with 5 mM nucleosides. Under these assay conditions, the enzyme phosphorylated all the four natural substrates (Table 1) . Introduction of the single or multiple point mutations resulted in an increased phosphorylation level of both deoxyguanosine (dGuo) and deoxyadenosine (dAdo) relative to dThd phosphorylation. No major differences in the relative phosphorylation levels for the C-terminal truncated D20 enzymes compared to the full-length proteins were observed. Accordingly, these data suggested that the mutations shifted the substrate specificity of the enzyme and resulted in increased phosphorylation of purine deoxyribonucleosides.
The mutant enzymes were tested for their ability to phosphorylate several purine and pyrimidine nucleoside analogs to determine if the altered substrate specificity also applied to nucleoside analog phosphorylation ( Table  2) . No phosphorylation of GCV was detected for the wild-type enzyme. All of the mutants phosphorylated GCV and the level of GCV phosphorylation was 10-30% compared to dThd phosphorylation. Other purine nucleoside analogs such as 9-b-D-arabinofuranosyladenine (araA), 9-b-D-arabinofuranosylguanine (araG) and 2 0 ,2 0 -difluorodeoxyguanosine (dFdG) were not phosphorylated by the wild-type enzyme, but were also phosphorylated by the mutant enzymes. The relative level of phosphorylation of araA and dFdG even exceeded the phosphorylation of dThd for several of the mutant proteins. The acyclic purine nucleoside analog 9-(2-hydroxyethoxymethyl)guanine (ACV) was not phosphorylated by either the wild-type enzyme or any of the mutants. In summary, these data suggest that the mutations introduced into Dm-dNK altered the substrate specificity of the enzyme to facilitate phosphorylation of naturally occurring purine deoxyribonucleosides as well as purine nucleoside analogs.
The Michaelis-Menten kinetic properties of the DmdNK proteins for dThd and GCV phosphorylation were determined (Table 3) Abbreviations: dAdo, deoxyadenosine; dCyd, deoxycytidine; dGuo, deoxyguanosine; Dm-dNK, Drosophila melanogaster deoxyribonucleoside kinase; dThd, deoxthymidine. The activities were measured with a phosphotransferase assay, and the specific activity is shown as nmol/mg/min7s.e. In parentheses is indicated the relative phosphorylation (%) compared to dThd phosphorylation for each individual protein.
Dm-dNK active-site mutants N Solaroli et al all decreased the affinity for dThd by E300-to 2000-fold and the V max for dThd phosphorylation was decreased E2-to 4-fold. Accordingly, the gain in the ability to phosphorylate purine nucleoside analogs by the mutant enzymes was accompanied by a loss in affinity for dThd. The D20 truncations of the M88R and M88R+V84A enzymes did not result in any marked increase in the catalytic rate for phosphorylation of either dThd or GCV. The highest GCV phosphorylation efficiency (V max /K m ) was observed for the M88R mutant enzyme whereas the other mutations had two-to eight-fold lower phosphorylation efficiencies. The triple mutant V84A+M88-R+A110D showed the lowest phosphorylation efficiency and also very low affinity for GCV with K m 45 mM. Because of the poor kinetic properties of this mutant enzyme, it was excluded from further studies.
We expressed the HSV-1 TK, wild-type Dm-dNK, the Dm-dNK D20 and four of the mutated proteins studied above in an osteosarcoma TK-deficient (OST TK À ) cell line to study how the expression of the proteins affected the sensitivity of the cells to cytotoxic nucleoside analogs. The proteins were expressed fused to green fluorescent protein (GFP) at their N-terminus to allow monitoring of protein expression and cell sorting. The cells expressing the enzymes showed green fluorescence in different subcellular compartments depending on the enzyme expressed. Cells expressing GFP, HSV-1 TK and the D20 versions of Dm-dNK showed cytosolic localization, whereas wild-type or mutant Dm-dNK containing the full-length proteins were localized in the nucleus (data not shown). These differences in subcellular localization of the Dm-dNK proteins are due to the presence of a nuclear targeting signal located in the C-terminal region of the protein. 4, 8 The sensitivity of the cell lines to several purine and pyrimidine nucleoside analogs was determined (Table 4) . Similar to previous studies, expression of wild-type Dm-dNK in the cells increased the sensitivity to pyrimidine nucleoside analogs such as (E)-5-(2-bromovinyl)-2 0 -deoxyuridine (BVDU) and 5-fluoro-2-deoxyuridine (FdU) 100-to 1000-fold. Expression of the wild-type enzyme also increased sensitivity 10-fold to dFdG but no increased sensitivity to other purine nucleoside analogs such as GCV, ACV, 9-4-(hydroxy-3-(hydroxymethyl)but-1-yl)guanine (PCV), araA or araG was observed. Expression of the D20 truncation of the Dm-dNK that has been reported to have higher catalytic rate in vitro 13 did not increase nucleoside analog sensitivity compared to the wild-type enzyme. The cells expressing Dm-dNK M88R showed similar sensitivity to the pyrimidine nucleoside analogs tested, but showed also E15-to 100-fold increased sensitivity to the purine nucleoside analogs GCV, PCV, araA, araG and dFdG. No increase in sensitivity to ACV was observed for any of the mutant enzymes investigated. The enhanced sensi- Abbreviations: ACV, 9-(2-hydroxyethoxymethyl)guanine; araA, 9-b-D-arabinofuranosyladenine; araC, 9-b-D-arabinofuranosylcytidine; araG,
Relative phosphorylation (%) compared to dThd phosphorylation for each individual protein (relative activities in % from 3 to 4 measurements7s.e. are given). Table 3 Kinetics properties of dThd and GCV phosphorylation by wild-type and different Dm-dNK mutants dThd GCV Dm-dNK active-site mutants N Solaroli et al tivity to purine nucleosides was lost when the M88R mutation was combined with V84A. The cells expressing this double mutant protein also lost the increased sensitivity to BVDU and FdU. No increased sensitivity to either purine or pyrimidine nucleoside analogs was observed for the D20 truncations of the proteins compared to the corresponding full-length proteins.
The cells expressing the HSV-1 TK showed a similar level of increased sensitivity to BVDU and FdU as the cell expressing wild-type Dm-dNK. However, the increase in sensitivity to GCV, PCV and ACV was superior with a 2000-, 1000-and 40-fold increased sensitivity, respectively. Expression of HSV-1 TK did not increase the sensitivity to the other tested purine nucleoside analogs. In summary, the Dm-dNK M88R protein that in vitro showed the highest efficiency for GCV phosphorylation also resulted in increased sensitivity to this nucleoside analog, as well as other purine nucleoside analogs, when expressed in cells. However, the increase in GCV sensitivity of cells expressing the Dm-dNK M88R was 100-fold lower than the increase in GCV sensitivity of cells expressing HSV-1 TK.
Discussion
It was recently reported that the substrate specificity of Dm-dNK could be altered by a few amino-acid substitutions. 12 The mutations were designed based on structural data with differences in the substrate binding pocket of the structurally related enzymes Dm-dNK and deoxyguanosine kinase (dGK).
14 Dm-dNK prefers pyrimidine nucleosides, whereas dGK only phosphorylates purine nucleosides and the rationale was to alter amino-acid residues in Dm-dNK into residues that would mimic the substrate binding site of dGK ( Figure 1 ). As Dm-dNK is an interesting candidate for suicide gene therapy given its high catalytic rate, it is of interest to be able to optimize the substrate recognition of the enzyme. A desirable property of a suicide gene would be a high phosphorylation activity for a broad range of substrates. This would allow a combination of different nucleoside analogs with different intracellular targets as well as a possibility to handle problems with toxic side effects and resistance development. The mutated enzymes reported by Knecht et al. 12 showed an increased affinity for purine deoxyribonucleosides and purine nucleoside analogs. They were also thoroughly studied regarding their kinetic properties for natural deoxyribonucleoside substrates, but not for purine nucleoside analogs. It should be very useful to be able to evaluate the use of purine nucleoside analogs, like GCV, dFdG or araG, in tumor cells transduced with Dm-dNK. We have previously demonstrated the efficiency of Dm-dNK as a suicide gene in tumor cell cultures. 8, 9 However, a potential weakness of this system was the poor bystander effect obtained by using the pyrimidine nucleoside BVDU as substrate. It was indeed observed that the bystander effect of purine nucleoside analogs in HSV-1 TK suicide gene therapy is by far superior to that of pyrimidine nucleoside analogs. 11 We, therefore, decided to further study and to determine the kinetic properties for the most interesting mutants reported by Knecht et al. 12 and also an additional double mutant against GCV and other nucleoside analogs. The aim of our studies was to identify the most promising purine nucleoside phosphorylating mutants for further evaluation in a cell culture system.
The efficiency of the activation of nucleoside analogs is dependent on the affinity of the nucleoside analog for the nucleoside kinase but also on the competition of natural substrates for the active site of the enzyme. Thus, in the present study, the ratio between dThd and GCV phosphorylation is important to consider for a novel suicide gene candidate. Two of the enzyme mutants in our study have previously been published as enzymes with improved purine nucleoside phosphorylation, 12 but this earlier study did not include kinetics of GCV phosphorylation. We decided that it was important to evaluate these mutants, and additional mutants affecting similar residues, in detail regarding their GCV and dThd kinetic properties. The single mutant M88R proved to be one of the most promising among the mutated enzymes tested. The M88R mutant Dm-dNK showed the lowest K m for GCV and a similar K m for dThd resulting in an The C-terminal 20 amino-acid truncated form of the M88R mutated enzyme did not show any improved GCV phosphorylating properties. Interestingly, there was a measurable phosphorylation of araG in the phosphoribosyl transfer assay for the truncated form of the M88R mutant indicating that the deletion of the 20 most C-terminal amino acids may affect the affinity of specific substrates. The 20 amino-acid deletion of the M88R+V84A double mutant clearly changed the K m for both dThd and GCV as compared with the untruncated M88R+V84A mutant. These mutants are the first identified to have a lower K m for GCV than for dThd. Although the K m values are very high and the overall efficiency is low for the M88R+V84A mutants, the ratio of GCV phosphorylation may be favorable. When expressed in cancer cell lines, the C-terminal truncation of the mutant Dm-dNKs did not provide an increase in the activity or in the sensitivity to the cytostatic activity of the compounds. This is in agreement with the observed kinetic properties (Table 3) where the decrease of K m or the increase of V max was not always related to the D20 deletion. It seemed more related to the nature of the mutation and/or the substrate. When expressed in a cancer cell line, the C-terminal truncation of the mutant Dm-dNKs did not provide an increased nucleoside analog sensitivity, with the exception of the M88R+V84A D20 transduced cells that were more sensitive towards GCV and ACV as compared with the M88R+V84A transduced cells. M88R D20, M88R+V84A and M88R+V84A D20 were the least active or sensitive mutants; the expression level quantified by fluorescenceactivated cell sorting (FACS) analysis showed, even after several sorting cycles, a very low level of GFP expression. This probably indicates how the stability of the protein is affected by the double mutant and/or the D20 deletion, even if this is not confirmed in Dm-dNK D20.
In general, the efficiency of the mutated enzymes to recognize GCV was confirmed in the cytotoxic assay although some differences were observed. It is also difficult to compare in vitro data with in vivo data as in both cases the enzymes were fused with different proteins that can affect the efficiency or the stability of the mutant. Besides, in the cell culture assay, different natural substrates compete with GCV, or the other investigated nucleoside analogs, at the substrate binding site of the enzyme resulting in more complex assay conditions and it is therefore expected that the in vitro kinetic determinations show some differences compared to the cell culture sensitivity data. The most promising mutant of the kinetic analysis, M88R, was the most interesting mutant also after transfection in OST TK À cancer cells. M88R transduction of the cells increased the sensitivity for GCV more than 10-fold although HSV-1 TK transduction was E300-fold more effective. Interestingly, the M88R Dm-dNK mutant dramatically increased the cytotoxicity of the anticancer nucleoside analogs araG and dFdG, and of other anti-herpetic guanine nucleoside analogs (i.e. ACV, PCV). AraG is specifically toxic to lymphoid cells and is not a substrate for HSV-1 TK. The M88R transduced cells showed an E100-fold increase in araG cytotoxicity in these non-lymphoid cells and thus suggest a novel promising suicide gene/ cytotoxic agent combination for gene therapy of tumors.
In conclusion, our investigations revealed mutant DmdNKs that show a much higher ratio of recognition of purine nucleoside analogs versus thymidine, compared to the wild-type enzyme. In addition, the M88R Dm-dNK expression in tumor cells revealed a dramatically increased cytotoxic potential for purine nucleoside analogs and in particular for the antileukemic compound araG. This is a unique property of the Dm-dNK M88R mutant that should be further investigated for its potential in suicide gene therapy.
Materials and methods

Site-directed mutagenesis
Site-directed mutagenesis of Dm-dNK was performed using the QuikChange site-directed mutagenesis kit (Stratagene, Heidelberg, Germany). Primers used are as follows: for MET88 to ARG88: 0 . The Dm-dNK mutations were verified by sequence determinations of both strands using an ABI 310 sequencer (Applied Biosystems, Foster City, CA, USA) and the BigDye cycle sequencing kit.
Expression and purification
We expressed the Dm-dNK cDNA in E. coli as a fusion protein to glutathione S-transferase. The plasmids were transformed into HMS174(DE3) (Novagen, Darmstadt, Germany) and single colonies were inoculated into LB medium supplemented with 100 mg/ml ampicillin. The bacteria were grown at 371C and protein expression was induced at OD 600 E0.8 with 1 mM isopropyl-1-thio-b-Dgalacto-pyranoside for E12 h at 271C. The expressed protein was purified using glutathione-sepharose 4B (Amersham Pharmacia Biotech, Uppsala, Sweden) as described. 15 The purity of the recombinant protein was verified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Phast system, Amersham Pharmacia Biotech) and the protein concentration was determined with the Bradford Protein Assay (Bio-Rad, Hercules, CA, USA) using bovine serum albumin as the concentration standard.
Enzyme assays
The activity of the purified recombinant enzymes was assayed in a 50 ml reaction mixture containing 50 mM Tris-HCl (pH 7.6), 0.1 mg/ml bovine serum albumin (BSA), 2.5 mM adenosine 5 0 triphosphate (ATP), 5 mM MgCl 2 and 5 mM dithiothreitol. For the substrate specificity, we used 0. H]-ganviclovir (MT 725, Moravek Biochemicals), and thymidine with concentration from 25 mM to 10 mM or ganciclovir with concentration from 500 mM to 20 mM, and 200 ng or Dm-dNK mutants. 16 The samples were incubated for 30 min at 371C and every 10 min 10 ml aliquots were spotted on Whatman DE-81 filter paper disks. The filters were dried for 1 h and washed 3 Â 5 min in 5 mM ammonium formate and once in sterile water. The filter-bound nucleoside monophosphates were eluted in 500 ml of 0.1 N HCl and 0.1 N KCl and the radioactivity was quantified by scintillation counting. The Michaelis-Menten constants were calculated using the GraphPad Prism software. All assays were performed at least in triplicate.
The substrate specificity of the purified enzymes was assayed by thin-layer chromatography as described. 17 Briefly, the assay was performed in 50 mM Tris-HCl (pH 7.6), 0.5 mg/ml BSA, 5 mM MgCl 2 , 5 mM dithiothreitol, 10 mM ATP, 15 mCi [g-32 P]ATP (Amersham Pharmacia Biotech), 1 mM of the nucleoside phosphoacceptor and 200 ng of recombinant Dm-dNK. The samples were incubated for 30 min at 371C, and then the reaction stopped with 25 mM ethylenediaminetetraacetic acid. A 2 ml portion of the reaction mixtures was spotted on polyethyleneimine-cellulose F thin-layer chromatography sheets (Merck, Darmstadt, Germany), and the nucleosides and nucleotides were separated in a buffer containing NH 4 OH:isobutyric acid:dH 2 O (1:66:33). The sheets were autoradiographed using phosphorimaging plates (BAS-1000, Fujix, Kyoto, Japan).
Construction of plasmid vectors
The Dm-dNK constructs and HSV-1 TK were cloned inside pEGFP-C2 vector (Clontech, Mountain View, CA, USA). The plasmids were purified using the Plasmid Midi kit (Qiagen, Hilden, Germany). The DNA sequence of the constructed plasmids was verified by DNA sequence determination using an ABI310 automated DNA sequencer (Applied Biosystem).
Cell culture and transfection
The OST TK À cells were cultured in Dulbecco's modified Eagle's medium. The media were supplemented with 10% (v/v) fetal calf serum (Gibco BRL, Carlsbad, CA, USA), 100 U/ml penicillin and 0.1 mg/ml streptomycin. Cells were grown at 371C in a humidified incubator with a gas phase of 5% CO 2 .
The plasmids were transfected into the human cell lines using FuGENE 6 transfection reagent (Roche, Basel, Switzerland). Then, 1 mg plasmid DNA and 3 ml FuGENE 6 were dissolved in Opti-MEM medium (Life Technologies, Carlsbad, CA, USA) and transfection was performed as described in the manufacturer's protocol. The cells were cultured for 2 weeks in the presence of 1 mg/ml Geneticin (Life Technologies Inc.) to select for stably transfected cell clones. Afterwards, the cells were sorted twice with FACS (BD FacsVantage SE with DIVA software equipped with a 488 nm laser) to select those expressing the GFP. GFP fluorescence was observed in a Nikon Eclipse E600 microscope equipped with a SPOT RT digital camera.
Cell proliferation assays
The cells were plated at E10 4 cells/well in 96-well plates and incubated in growth medium. After 24 h, different concentrations of nucleoside analogs were added. The medium containing the nucleoside analogs was changed once during the 3-4 days incubation. Cell survival was assayed by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (Boehringer Mannheim, Vienna, Austria) after 3-4 days of drug exposure. The inhibition constant (IC) 50 was defined as the drug concentration required to inhibit cell proliferation by 50%. Each experiment was performed in triplicate.
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